Will a new tablet match the capsule for hot flash relief?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female participants aged 18 to 65 years (inclusive) at the time of signing informed consent. * Participants must be overtly healthy as determined by the investigator based on medical history, physical examination, vital signs, ECG, and clinical laboratory assessments. * Body weight ≥50 kg and body mass index (BMI) between 18.0 and 32.0 kg/m² (inclusive) at screening. * Women of childbearing potential must agree to use a highly effective method of contraception during the study and until 14 days after last administration of study intervention. * Signed informed consent obtained prior to any study-specific procedures. Exclusion Criteria: * Diseases or conditions that may affect absorption, distribution, metabolism, elimination, or effects of the study intervention(s). * Known or suspected hypersensitivity to the study intervention(s) or their excipients. * Severe allergies or clinically significant hypersensitivity reactions (e.g. allergic asthma, urticaria, or steroid-requiring allergies). * Febrile illness within 2 weeks prior to first administration of study intervention. * History of clinically relevant seizures or endometrial tumors. * Use of moderate or strong CYP3A4 inhibitors or inducers within 4 weeks prior to first study intervention. * Participation in another clinical study within 30 days prior to first study intervention or concurrent participation in another trial. * Clinically relevant abnormal laboratory findings at screening, including elevated liver enzymes or positive virology tests. * Positive pregnancy test at screening or prior to dosing, or breastfeeding. Positive drug abuse or alcohol test at screening. * Smoking more than 10 cigarettes per day within 3 months prior to screening. * Special diets incompatible with study requirements or inability to comply with study procedures.